RIBOMIC Inc. is engaged in the drug discovery business based on the platform Ribomic Aptamer Refined Therapeutics System related to aptamer drug discovery technology. Its drug discovery business is divided into self discovery and co-discovery divisions. Self Drug Discovery division develops aptamer and licenses and out the results to pharmaceutical companies. The Co-Discovery division earns the research expenses paid by the alliance partner for the shared part of co-discovery business with alliance pharmaceutical companies researching aptamer pharmaceutical.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
03/07/26	JPY 66.00	+3.12%	106,100
02/07/26	JPY 64.00	+1.59%	364,500
01/07/26	JPY 63.00	+3.28%	207,000
30/06/26	JPY 61.00	0.00%	139,700
29/06/26	JPY 61.00	+3.39%	703,400

Delayed Quote Japan Exchange

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

Market Closed - Japan Exchange Other stock markets 04:30:00 03/07/26 pm AEST			5-day change	1st Jan Change
66.00 ^JPY	+3.12%		+13.79%	-15.38%

02/07	Ribomic Enrolls First Patient in Phase III Trials of Umedaptanib Pegol for Achondroplasia Treatment	MT
14/05	Ribomic Inc. Reports Earnings Results for the Full Year Ended March 31, 2026	CI

Market Cap	3.69B 22.9M 20.02M 18.39M 17.15M 32.52M 2.18B 33.01M 221M 85.85M 1.07B 85.94M 84.1M	P/E 2025	-3.89x	P/E 2026	-3.82x
Enterprise Value	866M 5.37M 4.69M 4.31M 4.02M 7.62M 511M 7.74M 51.77M 20.12M 251M 20.15M 19.71M	EV / Sales 2025	666x	EV / Sales 2026	651x
Free-Float	96.35%	Yield 2025 *	-	Yield 2026	-

02/07	Ribomic Enrolls First Patient in Phase III Trials of Umedaptanib Pegol for Achondroplasia Treatment	MT
14/05	Ribomic Inc. Reports Earnings Results for the Full Year Ended March 31, 2026	CI
19/03	Ribomic Files IND For Phase III Trial Of Achondroplasia Drug In Japan	MT
19/03	Ribomic Inc Announces IND Application for Phase III Clinical Trial of Umedaptanib Pegol for Achondroplasia Treatment	CI
10/03	Ribomic Reports Positive Phase II Results For Achondroplasia Drug	MT
10/03	Ribomic, Inc. Announces Summary Report on Primary Endpoint for Phase Ii Clinical Trial of Umedaptanib Pegol in the Treatment of Achondroplasia	CI
12/02	Ribomic Inc. Reports Earnings Results for the Nine Months Ended December 31, 2025	CI
14/01	Ribomic Files Patent for Anti-Autotaxin Aptamer RBM-006	MT
14/01	RIBOMIC, Inc. Announces New Substance Patent Application for Highly Active RBM-006 (Anti-Autotaxin Aptamer) and its Drug Impact in a Mouse Model of Diabetic Retinopathy	CI
21/11	Ribomic Shows Sustained Two-Year Gains in Achondroplasia Trial	MT
07/10/25	Ribomic Reports Positive Phase 2 Results for Achondroplasia Drug Umedaptanib Pegol	MT
07/10/25	Ribomic, Inc. Announces Positive Phase 2 Cohort 2 Results for Umedaptanib Pegol in Achondroplasia, Demonstrating an Increase in the Annualized Growth Rate of Up to +5.0 Cm/Year with Biweekly Administration in Children Aged 5 Years and Older	CI
07/10/25	Ribomic announces positive phase 2 cohort 2 results for umedaptanib pegol in achondroplasia	RE

07/10/25	RIBOMIC Announces Positive Phase 2 Cohort 2 Results for Umedaptanib Pegol in Achondroplasia, Demonstrating an Increase in the Annualized Growth Rate of up to +5.0 cm/year with Biweekly Administration in Children Aged 5 Years and Older	BU
05/11/24	RIBOMIC Announces Positive Interim Results from Phase IIa Trial of umedaptanib pegol in Achondroplasia Demonstrating Increase in Annualized Growth Rate of up to +4.6 cm/year in Children 5 Years of Age and Older in the Low Dose Cohort	BU
04/08/24	RIBOMIC Announces Completion of Patient Enrollment in Early Phase II Study of umedaptanib pegol for Achondroplasia and Initiation of Dosing in Cohort 2 of Early Phase II Clinical Study	BU
05/12/23	RIBOMIC Phase I and II Data Published in the Eye: Full TOFU/RAMEN/TEMPURA Trial Results Demonstrate Clinical Proof of Concept of Umedaptanib Pegol in Exudative Age-Related Macular Degeneration (nAMD)	BU
29/07/22	RIBOMIC : Announces Issuance of US Patent for its RBM-010, Novel Drug Candidate for Osteoarthritis	PU

Ribomic Inc. Stock

Stocks

4591

JP3974850004

Biotechnology & Medical Research

Valuation: Ribomic Inc.

Chart: Ribomic Inc.

Latest news : Ribomic Inc.

Press Releases: Ribomic Inc.

News in other languages: Ribomic Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Ribomic Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

08/10/25	RIBOMIC veröffentlicht positive Ergebnisse der Phase-2-Kohorte 2 für Umedaptanib Pegol bei Achondroplasie, die eine Steigerung der annualisierten Wachstumsrate um bis zu +5,0 cm/Jahr bei zweiwöchentlicher Verabreichung bei Kindern ab 5 Jahren zeigen
06/11/24	RIBOMIC gibt positive Zwischenergebnisse der Phase-IIa-Studie mit Umedaptanib Pegol bei Achondroplasie bekannt, die eine Steigerung der annualisierten Wachstumsrate von bis zu +4,6 cm/Jahr bei Kindern ab 5 Jahren in der niedrig dosierten...
20/02/20	RIBOMIC : kündigt erste Injektion in der klinischen Phase-2-Studie von RBM-007 (TOFU-Studie) bei Patienten mit feuchter altersbedingter Makula-Degeneration an
19/06/19	RIBOMIC : gibt positive Topline-Ergebnisse der klinischen Phase-1/2a-Studie an RBM-007 (SUSHI-Studie) bei Patienten mit feuchter altersbedingter Makuladegeneration bekannt

1 day	+3.13%
1 week	+13.79%
Current month	+8.20%
1 month	-4.35%
3 months	-26.67%
6 months	-15.38%
Current year	-15.38%

Manager	Title	Age	Since
Yoshikazu Nakamura PSD	President	78	01/04/2012
Toshiya Imai DFI	Director of Finance/CFO	-	-
Takeo Adachi CTO	Chief Tech/Sci/R&D Officer	38	01/10/2023

Director	Title	Age	Since
Yoshikazu Nakamura BRD	Director/Board Member	78	01/10/2005
Toshiaki Nishihata BRD	Director/Board Member	77	01/06/2016
Takeo Adachi BRD	Director/Board Member	38	01/06/2024

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
RIBOMIC INC.	+3.12%	+13.79%	-32.65%	-58.49%	22.25M
ARGENX SE	+0.68%	+5.92%	+80.45%	+137.78%	58.73B
WUXI APPTEC CO., LTD.	+2.32%	+5.89%	+76.81%	+99.20%	53.92B
BIONTECH SE	-10.61%	+8.38%	-9.90%	-9.62%	24.67B
INSMED INCORPORATED	-0.30%	+6.82%	+13.60%	+428.91%	24.19B
WUXI BIOLOGICS (CAYMAN) INC.	+4.74%	+13.47%	+46.43%	+0.03%	18.8B
GENMAB A/S	-0.29%	+9.78%	+44.62%	-27.94%	17.61B
PHARMAESSENTIA CORPORATION	0.00%	+16.74%	+171.12%	+355.99%	16.25B
EXELIXIS, INC.	+3.50%	+4.92%	+26.07%	+192.26%	14.04B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+6.72%	+20.94%	+51.67%	-	13.9B
Average	+2.90%	+7.48%	+46.82%	+124.23%	24.21B
Weighted average by Cap.	+2.44%	+5.53%	+59.78%	+138.33%

	2025	2026
Net sales	2M 12.4K 10.84K 9.96K 9.29K 17.61K 1.18M 17.88K 120K 46.5K 580K 46.55K 45.55K	3M 18.6K 16.26K 14.94K 13.93K 26.42K 1.77M 26.82K 179K 69.74K 871K 69.82K 68.32K
Net income	-1.02B -6.31M -5.52M -5.07M -4.73M -8.97M -601M -9.1M -60.88M -23.67M -295M -23.69M -23.18M	-1.14B -7.1M -6.21M -5.7M -5.32M -10.08M -676M -10.24M -68.47M -26.62M -332M -26.65M -26.08M
Net Debt	-3.04B -18.83M -16.46M -15.13M -14.1M -26.75M -1.79B -27.15M -182M -70.6M -881M -70.68M -69.17M	-2.83B -17.53M -15.32M -14.08M -13.13M -24.9M -1.67B -25.27M -169M -65.72M -820M -65.8M -64.38M

1 week	58	66
1 month	57	68
Current year	57	120
1 year	57	127
3 years	57	159
5 years	57	944
10 years	57	1,109